Nijmegen

• LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting
  2025-522338-30-00 4 2026-03-31 Ulcerative Colitis
• Phase 2a Study of Tafasitamab in Adults With Primary Autoimmune Blood Cell Disorders Recruiting
  2025-521286-27-00 10 2026-03-26 Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimm
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• The PEARL trial: Prevention of hepatic Encephalopathy by administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoi … Recruiting
  2024-512040-28-01 6 2026-03-01 Confirmed diagnosis of Alcoholic liver cirrhosis
• Effects of ziltivekimab on coronary atherosclerotic burden in patients with acute myocardial infarction Recruiting
  2024-520364-34-00 5 2026-02-23 Acute myocardial infarction
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma Recruiting
  2025-522640-41-00 4 2026-02-13 Asthma
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Metastatic Clear Cell Renal Cell Carcinoma
• IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator … Recruiting
  2025-522500-24-00 5 2026-01-20 Head and Neck squamous cell carcinoma
• Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-mo … Recruiting
  2024-516756-18-00 5 2026-01-19 Parkinson's disease
• A Study to test ALE.P03 in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Recruiting
  2025-521441-24-00 7 2026-01-19 Advanced or Metastatic Solid Tumors
• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Subjects With Primary Membranous Nephropathy Recruiting
  2025-521661-27-00 10 2025-12-19 Primary Membranous Nephropathy
• A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting
  2025-520825-19-00 5 2025-12-16 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Ber
• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting
  2025-522860-34-00 5 2025-12-16 Chronic lymphocytic leukemia (CLL)
• Anti-inflammatory drug to prevent complications in type 1 diabetes Recruiting
  2025-521397-34-00 11 2025-12-15 Type 1 Diabetes
• EPIK-P4: A Phase II single-arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patien … Recruiting
  2024-519960-42-00 4 2025-12-11 PIK3CA-Related Overgrowth Spectrum (PROS)
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 5 2025-12-09 High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alt
• A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non … Recruiting
  2024-515125-28-00 4 2025-12-08 Non-obstructive hypertrophic cardiomyopathy
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor

Showing 121–144 of 568 trials